Abstract
Introduction
The BLAZE study reported the superiority of an approved dual bronchodilator, QVA149 (GOLD group B-D), in terms of improvement in self-administered computerised version of transitional dyspnoea index (SAC-TDI) total score and lung function vs placebo (PBO) and tiotropium (TIO) in patients (pts) with COPD.1 Here, we present improvements in dyspnoea, lung function, and rescue medication use in the subgroup of pts on prior LAMA therapy.
Methods
In this blinded, double-dummy, 3-period crossover study, pts (with mMRC≥2) with moderate-to-severe COPD were randomised to once-daily QVA149 110/50µg, PBO or TIO 18µg.
Results
Of the 247 pts randomised, 115 were on prior LAMA therapy. Of these 115 pts, a higher proportion of pts on QVA149 reported ≥1unit improvement in the SAC-TDI total score (36.5%) vs PBO (16.4%; odds ratio [OR] 3.71; p<0.001) and TIO (20.2%; OR 2.51; p=0.007). At Day 1 and Wk 6, QVA149 provided significant improvements in mean FEV1 at all assessed time-points and FEV1 AUC0–4h vs both PBO and TIO (table). QVA149 significantly reduced (p<0.001) mean daily rescue medication use (puffs/day) by 1.55 vs PBO and by 0.68 vs TIO.
Conclusion
In the subgroup of pts on prior LAMA therapy, QVA149 significantly improved SAC-TDI total score and lung function while also reducing rescue medication usage vs PBO and TIO.
Reference:
1. Mahler et al. Eur Respir J 2013 Oct 31 (in press).
- © 2014 ERS